KCNIP1

Last update 08 May 2025

Basic Info

Synonyms

A-type potassium channel modulatory protein 1, KCHIP1, KCNIP1

+ [5]

Introduction

Regulatory subunit of Kv4/D (Shal)-type voltage-gated rapidly inactivating A-type potassium channels (PubMed:10676964, PubMed:11423117, PubMed:17187064, PubMed:34552243, PubMed:34997220). Regulates channel density, inactivation kinetics and rate of recovery from inactivation in a calcium-dependent and isoform-specific manner (PubMed:10676964, PubMed:11423117, PubMed:17187064, PubMed:34552243, PubMed:34997220). In vitro, modulates KCND1/Kv4.1 and KCND2/Kv4.2 currents (PubMed:34552243). Increases the presence of KCND2 at the cell surface (PubMed:12829703).

100 Clinical Results associated with KCNIP1

100 Translational Medicine associated with KCNIP1

0 Patents (Medical) associated with KCNIP1

116

Literatures (Medical) associated with KCNIP1

01 May 2024·Journal of Clinical Investigation

Induction of antiviral interferon-stimulated genes by neuronal STING promotes the resolution of pain in mice

Article

Author: Soubeyre, Vanessa ; Agosti, Francina ; Lonjon, Nicolas ; Vachiery-Lahaye, Florence ; Bauchet, Luc ; Gill, Gurveer ; Chiu, Isaac M ; Bourinet, Emmanuel ; Basso, Lilian ; Bradaia, Amyaouch ; Defaye, Manon ; Iftinca, Mircea ; Svendsen, Kristofer ; Poulen, Gaetan ; Ozmaeian, Aye ; Gheziel, Nadine ; Abdullah, Nasser S ; Altier, Christophe ; Martin, Jérémy ; Delanne-Cuménal, Mélissa

Inflammation and pain are intertwined responses to injury, infection, or chronic diseases. While acute inflammation is essential in determining pain resolution and opioid analgesia, maladaptive processes occurring during resolution can lead to the transition to chronic pain. Here we found that inflammation activates the cytosolic DNA-sensing protein stimulator of IFN genes (STING) in dorsal root ganglion nociceptors. Neuronal activation of STING promotes signaling through TANK-binding kinase 1 (TBK1) and triggers an IFN-β response that mediates pain resolution. Notably, we found that mice expressing a nociceptor-specific gain-of-function mutation in STING exhibited an IFN gene signature that reduced nociceptor excitability and inflammatory hyperalgesia through a KChIP1-Kv4.3 regulation. Our findings reveal a role of IFN-regulated genes and KChIP1 downstream of STING in the resolution of inflammatory pain.

17 Feb 2024·Clinical Infectious Diseases

Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Article

Author: Doernberg, Sarah ; Howard-Anderson, Jessica ; Hamasaki, Toshimitsu ; Holland, Thomas L. ; Nambiar, Sumati ; Hamasaki, Toshi ; Evans, Scott R. ; Doernberg, Sarah B. ; Collyar, Deborah ; Kinamon, Tori ; Holland, Tom ; Chambers, Henry F. ; Hill, Carol ; Tsalik, Ephraim ; Fowler, Vance ; Leister-Tebbe, Heidi ; Boucher, Helen W. ; Evans, Scott ; Geres, Holly ; Rubin, Daniel ; Rubin, Dan ; Dai, Weixiao ; King, Heather ; Boucher, Helen ; Kim, Peter ; Natarajan, Mukil ; Fowler, Vance G. Jr. ; Nambiar, Sumathi ; Needles, Mark ; Cosgrove, Sara ; Waack, Ursula ; Gopinath, Danaher Ramya

AbstractBackgroundHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are frequently caused by multidrug-resistant organisms. Patient-centered endpoints in clinical trials are needed to develop new antibiotics for HABP/VABP. Desirability of outcome ranking (DOOR) is a paradigm for the design, analysis, and interpretation of clinical trials based on a patient-centered, benefit-risk evaluation.MethodsA multidisciplinary committee created an infectious diseases DOOR endpoint customized for HABP/VABP, incorporating infectious complications, serious adverse events, and mortality. We applied this to 2 previously completed, large randomized controlled trials for HABP/VABP. ZEPHyR compared vancomycin to linezolid and VITAL compared linezolid to tedizolid. For each trial, we evaluated the DOOR distribution and probability, including DOOR component and partial credit analyses. We also applied DOOR in subgroup analyses.ResultsIn both trials, the HABP/VABP DOOR demonstrated similar overall clinical outcomes between treatment groups. In ZEPHyR, the probability that a participant treated with linezolid would have a more desirable outcome than a participant treated with vancomycin was 50.2% (95% confidence interval [CI], 45.1%−55.3%). In VITAL, the probability that a participant treated with tedizolid would have a more desirable outcome than a participant treated with linezolid was 48.7% (95% CI, 44.8%–52.6%). The DOOR component analysis revealed that participants treated with tedizolid had a less desirable outcome than those treated with linezolid when considering clinical response alone. However, participants with decreased renal function had improved overall outcomes with tedizolid.ConclusionsThe HABP/VABP DOOR provided more granular information about clinical outcomes than is typically presented in clinical trials. HABP/VABP trials would benefit from prospectively using DOOR.

01 Dec 2023·Applied Microbiology and Biotechnology

Host genetics and gut microbiota jointly regulate blood biochemical indicators in chickens

Article

Author: Li, Xiaochang ; Lan, Fangren ; Jin, Jiaming ; Zhong, Conghao ; Zhang, Boxuan ; Li, Junying ; Wen, Chaoliang ; Zhou, Qianqian ; Jiang, Xinwei ; Sun, Congjiao ; Yang, Ning

AbstractBlood biochemical indicators play a crucial role in assessing an individual’s overall health status and metabolic function. In this study, we measured five blood biochemical indicators, including total cholesterol (CHOL), low-density lipoprotein cholesterol (LDL-CH), triglycerides (TG), high-density lipoprotein cholesterol (HDL-CH), and blood glucose (BG), as well as 19 growth traits of 206 male chickens. By integrating host whole-genome information and 16S rRNA sequencing of the duodenum, jejunum, ileum, cecum, and feces microbiota, we assessed the contributions of host genetics and gut microbiota to blood biochemical indicators and their interrelationships. Our results demonstrated significant negative phenotypic and genetic correlations (r = − 0.20 ~ − 0.67) between CHOL and LDL-CH with growth traits such as body weight, abdominal fat content, muscle content, and shin circumference. The results of heritability and microbiability indicated that blood biochemical indicators were jointly regulated by host genetics and gut microbiota. Notably, the heritability of HDL-CH was estimated to be 0.24, while the jejunal microbiability for BG and TG reached 0.45 and 0.23. Furthermore, by conducting genome-wide association study (GWAS) with the single-nucleotide polymorphism (SNPs), insertion/deletion (indels), and structural variation (SV), we identified RAP2C, member of the RAS oncogene family (RAP2C), dedicator of cytokinesis 11 (DOCK11), neurotensin (NTS) and BOP1 ribosomal biogenesis factor (BOP1) as regulators of HDL-CH, and glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5), dihydrodiol dehydrogenase (DHDH), and potassium voltage-gated channel interacting protein 1 (KCNIP1) as candidate genes of BG. Moreover, our findings suggest that cecal RF39 and Clostridia_UCG_014 may be linked to the regulation of CHOL, and jejunal Streptococcaceae may be involved in the regulation of TG. Additionally, microbial GWAS results indicated that the presence of gut microbiota was under host genetic regulation. Our findings provide valuable insights into the complex interaction between host genetics and microbiota in shaping the blood biochemical profile of chickens.Key points• Multiple candidate genes were identified for the regulation of CHOL, HDL-CH, and BG.• RF39, Clostridia_UCG_014, and Streptococcaceae were implicated in CHOL and TG modulation.• The composition of gut microbiota is influenced by host genetics.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

KCNIP1

Basic Info

Related

Analysis